Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

JAMA otolaryngology-- head & neck surgery - 1 Jun 2015

Wirtz Eric D, Hoshino Daisuke, Maldonado Anthony T, Tyson Darren R, Weaver Alissa M

Abstract excerpt

IMPORTANCE: The PIK3CA mutation is one of the most common mutations in head and neck squamous cell carcinoma (HNSCC). Through this research we attempt to elicit the role of oncogene dependence and effects of targeted therapy on this PIK3CA mutation. OBJECTIVES: (1) To determine the role of oncogene dependence on PIK3CA-one of the more common and targetable oncogenes in HNSCC, and (2) to evaluate the consequence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Lactams, Macrocyclic

Share to Pyridones

Share to Pyrimidinones

Share to Quinolines

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 25855885
DOI: 10.1001/jamaoto.2015.0471
PMCID: PMC4474763

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.PMID 25855885Read ↗

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.Semantic proximity Read ↗

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistanceSemantic proximity Read ↗

Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Semantic proximity Read ↗

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerSemantic proximity Read ↗

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.Semantic proximity Read ↗

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.Semantic proximity Read ↗

The PIK3CA gene as a mutated target for cancer therapy.Semantic proximity Read ↗

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsSemantic proximity Read ↗

Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.Semantic proximity Read ↗

Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.Semantic proximity Read ↗

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.Semantic proximity Read ↗

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.